BioStock: Coegin Pharma applies for clinical study application
There is a high demand for new innovative treatments against the precancerous skin condition actinic keratosis (AK). In the Nordics, Coegin Pharma is developing a drug targeting the cPLA₂α enzyme, which is involved in several inflammatory diseases, cancers and pre-cancerous conditions like AK. This week, the company submitted an application to the Danish Medicines Agency to begin a clinical trial with the drug candidate AVX001.
Read the full article at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/